Pfizer Ventures and Earlybird Venture Capital co-led the financing, which also included funding from new investors Oxford Science Enterprises and British Patient Capital as well as existing investors Canaan and Andera Partners.

The proceeds from the financing will support the continued development of the company's immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens. This includes the anticipated advancement of the company's lead asset, GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023.

Grey Wolf Therapeutics said that its therapeutic strategy is centered on generating immune responses against tumors thereby overcoming key resistance mechanisms to current immuno-oncology therapy such as poor tumor recognition by T cells and T-cell exhaustion.

This is achieved through targeted inhibition of the endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), which enables the generation and presentation of potent cancer antigens to the surface of tumor cells, in turn eliciting a de novo T-cell response against tumors, the firm added.

Afami-cel trial shows anti-tumor activity
University of Texas MD Anderson Cancer Center researchers achieved clinically significant results for patients with multiple solid tumor types in a Phase...

Biogen reaches agreement with Samsung Biologics
Biogen has reached an agreement with Samsung Biologics to sell an equity stake in the companies' biosimilar joint venture for up to $2.3 billion....

Experimental drug enhances immunotherapy against pancreatic cancer in mice
A combination treatment that included an experimental small molecule drug not only led to a reduction in tumor growth in murine models of pancreatic cancer,...

Dual-antigen CAR T system could be effective at treating solid tumors in children
A new chimeric antigen receptor (CAR) T-cell system that targets two tumor antigens may be effective at treating difficult solid tumors in children in...